CTLA4 and neoplasm: In pre-clinical studies, the depletion of Tregs with anti-CTLA-4, anti-CD25 or CCR5 inhibitor r reduced tumor growth and prolonged the animals’ survival by enhancing the activation of tumor specific T cells.